コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 dobacterium was negatively associated with 5-hydroxytryptamine.
2 eater solution stability than alpha-methyl-5-hydroxytryptamine.
4 ibroblast growth factor receptor 1 (FGFR1)-5-hydroxytryptamine 1A (5-HT1A) receptor complexes have be
5 altered through serotonergic modulation of 5-hydroxytryptamine 1A (5-HT1A) receptors, which hyperpola
7 agonist radioligand for the serotonin 1A (5-hydroxytryptamine 1A [5-HT1A]) receptor in recombinant c
9 ivation of G(i), by comparing Smo with the 5-hydroxytryptamine(1A) (5-HT(1A)) receptor, a quintessent
10 measurement of activation of the serotonin 5-hydroxytryptamine-1A (5-HT(1A)) receptor expressed in CH
12 evidence implicates the serotonin receptor 5-hydroxytryptamine 1B (5-HT1B) in the effects of cocaine.
14 y that GSK3beta selectively interacts with 5-hydroxytryptamine-1B receptors (5-HT1BR) that have impor
16 led as a GPCR heteromer with the serotonin 5-hydroxytryptamine 2A (5-HT(2A)) receptor in the mouse fr
20 of neuroscience and clinical research into 5-Hydroxytryptamine 2A (5-HT2A) receptor agonists, such as
22 The D2 dopamine receptor and the serotonin 5-hydroxytryptamine 2A receptor (5-HT2A) are closely-relat
25 gene expression patterns of the 5-HT(2A) (5-hydroxytryptamine 2A) and 5-HT(1A) (5-hydroxytryptamine
27 ibosomal S6 kinase 2 (RSK2) interacts with 5-hydroxytryptamine(2A) (5-HT(2A)) serotonin receptors and
30 s suggest that cis-UCA binds to serotonin (5-hydroxytryptamine) 2A (5-HT(2A)) receptor and that antag
31 ocked by SB742457 but not by the selective 5-hydroxytryptamine-2A (5HT2A) antagonist ketanserin) and
32 on the postsynaptic serotonin-2A receptor (5-hydroxytryptamine-2A, or 5-HT2A) status were investigate
33 n structure of a complex between the human 5-hydroxytryptamine 2B (5-HT2B) receptor and an antibody F
34 ssessed whether these polymorphisms affect 5-hydroxytryptamine 2B (5-HT2B) receptor in vitro pharmaco
35 atory function requires stimulation of the 5-hydroxytryptamine 2B receptor (5-HT(2B)) on HSCs by sero
37 intensity arising from fluorescence-tagged 5-hydroxytryptamine 2C (5-HT(2C)) receptors diffusing with
38 press an eGFP-tagged form of the serotonin 5-hydroxytryptamine 2C (5-HT2C) receptor, global analysis
43 hod is based on the serotonin 2C receptor (5-hydroxytryptamine(2C); 5HT(2C)) transcript, an RNA editi
46 ] receptor antagonist) and palonosetron (a 5-hydroxytryptamine-3 [5-HT3] receptor antagonist) for the
47 management up to 72 h with the long-acting 5-hydroxytryptamine-3 receptor antagonist palonosetron.
49 sensory cortex of the mouse, the serotonin 5-hydroxytryptamine 3A (5-HT(3A)) receptor, the only ionot
50 e all-atom MD simulations of the homomeric 5-hydroxytryptamine 3A (5-HT(3A)) serotonin receptor for 1
51 has greater potency at mouse than at human 5-hydroxytryptamine 3A (5-HT3A) receptors, despite 84% ami
52 main 2 (TM2) to the TM2-TM3 loop, in mouse 5-hydroxytryptamine(3A) (5-HT(3A)) receptor function was p
53 ted manner(4) by enzymatic conversion from 5-hydroxytryptamine (5-HT or serotonin), and modulates sle
54 serve the dynamic binding and unbinding of 5-hydroxytryptamine (5-HT) (i.e., serotonin) to the bindin
57 velopment of a PET radioligand for imaging 5-hydroxytryptamine (5-HT) 6 receptors in the brain would,
59 ent activated by maximal concentrations of 5-hydroxytryptamine (5-HT) and increased the magnitude of
60 ed segments of native mouse intestine with 5-hydroxytryptamine (5-HT) and prostaglandin E2 (PGE2) ind
62 gh there is general agreement that mucosal 5-hydroxytryptamine (5-HT) can initiate peristaltic reflex
63 blot, whereas tryptophan, kynurenine, and 5-hydroxytryptamine (5-HT) concentrations were quantified
66 ansport protein which re-uptakes excessive 5-hydroxytryptamine (5-HT) from effective location to term
68 (SERT) is responsible for the re-uptake of 5-hydroxytryptamine (5-HT) from the synaptic cleft after r
70 m) revealed significantly higher levels of 5-hydroxytryptamine (5-HT) in the striatum and hippocampus
71 ation of cultured smooth muscle cells with 5-hydroxytryptamine (5-HT) induced PAK1 phosphorylation at
78 ng reversal learning, whilst orbitofrontal 5-hydroxytryptamine (5-HT) likely mediates this type of lo
79 sent studies examined the acute effects of 5-hydroxytryptamine (5-HT) on NHE activity using Caco-2 ce
84 ad use of short-acting antagonists for the 5-hydroxytryptamine (5-HT) receptor, about 50% of patients
85 for beta-arrestin signaling at the 5-HT2B 5-hydroxytryptamine (5-HT) receptor, whereas they are rela
86 tify that both ionotropic and metabotropic 5-hydroxytryptamine (5-HT) receptors are expressed on whis
87 ced inactivation and reactivation of human 5-hydroxytryptamine (5-HT) receptors in a recombinant cell
89 ene (Itgb3) on SERT function and selective 5-hydroxytryptamine (5-HT) reuptake inhibitor (SSRI) effec
90 er inhibitor Prozac, the inhibition of the 5-hydroxytryptamine (5-HT) transporter by the ion channel
91 KM Apl III in the sensory neuron 2 d after 5-hydroxytryptamine (5-HT) treatment reversed persistent n
95 d Sf9 cells, we show the inhibition of [3H]5-hydroxytryptamine (5-HT) uptake and [3H]dihydrotetrabena
96 mucus release stimulated by either PGE2 or 5-hydroxytryptamine (5-HT) was approximately half that sti
99 function in vivo led to reduced serotonin (5-hydroxytryptamine (5-HT)) blood levels that paralleled a
100 microbiota regulates levels of serotonin (5-hydroxytryptamine (5-HT)) in the intestinal epithelium a
104 pse is dynamically regulated by serotonin (5-hydroxytryptamine (5-HT)) with elevated levels leading t
105 to elevated levels of embryonic serotonin (5-hydroxytryptamine (5-HT)), and we found that knockdown o
112 Na(+) for driving transport and promoting 5-hydroxytryptamine (5-HT)-dependent conformational change
115 ression in golden hamsters is inhibited by 5-hydroxytryptamine (5-HT)1A receptors and facilitated by
117 at acute stressors can increase serotonin [5-hydroxytryptamine (5-HT)] concentrations in the dorsomed
118 dy of literature has implicated serotonin [5-hydroxytryptamine (5-HT)] in descending modulation of no
122 The dynamic interplay between serotonin [5-hydroxytryptamine (5-HT)] neurotransmission and the hypo
124 oded Ile, Asn, and Ile (INI) of serotonin [5-hydroxytryptamine (5-HT)] receptor 2C (5-HT(2C)R) with V
125 dence that cis-UCA binds to the serotonin [5-hydroxytryptamine (5-HT)] receptor with relatively high
132 e foremost hypothesis of depression is the 5-hydroxytryptamine (5-HT, serotonin) deficiency hypothesi
133 th a prenatal, genetically induced loss of 5-hydroxytryptamine (5-HT, serotonin) neurones are comprom
134 have found that the serotonin 1B receptor [5-hydroxytryptamine (5-HT1B) receptor] interacts with p11.
135 was reversed by systemic treatment with a 5-hydroxytryptamine (5-HT2C) receptor agonist and mimicked
136 ssion in the central nervous system (CNS), 5-hydroxytryptamine (5-HT: serotonin) subtype 6 receptor (
137 responsible for reuptake and recycling of 5-hydroxytryptamine (5-HT; serotonin) after its exocytotic
140 and some other transmitters, estimation of 5-hydroxytryptamine (5-HT; Serotonin) release has proved t
141 ion studies suggest that variations in the 5-hydroxytryptamine (5-HT; serotonin) transporter (5-HTT)
146 We tested the hypothesis that serotonin (5-hydroxytryptamine [5-HT]) exerts stimulatory and inhibit
148 suggested an important role for serotonin (5-hydroxytryptamine [5-HT]) in enhancing the counterregula
153 Bag cell neurons exposed to serotonin (5-hydroxytryptamine [5-HT]) respond with a threefold incre
154 ifferent pruritogens, including serotonin (5-hydroxytryptamine [5-HT]), histamine, SLIGRL (protease-a
161 teroid (AAS) exposure and brain serotonin (5-hydroxytryptamine, 5-HT) depletion on behavior of pubert
162 as induced by an increase in serotonergic (5-hydroxytryptamine, 5-HT) efficacy has been a target of a
163 ssociated with abnormalities in serotonin (5-hydroxytryptamine, 5-HT) in regions of the brainstem cri
164 eus (DR) is the major source of serotonin (5-hydroxytryptamine, 5-HT) in the forebrain and dysfunctio
170 g RVM neurons, we found that serotonergic (5-hydroxytryptamine, 5-HT) neurons decreased by 35% ipsila
172 ration to examine the effect of serotonin (5-hydroxytryptamine, 5-HT) receptor activation on segmenta
173 he nuclei and expresses several serotonin (5-hydroxytryptamine, 5-HT) receptor subtypes, including th
175 trafficking of single groups of serotonin (5-hydroxytryptamine, 5-HT) receptors using single quantum
176 e oxidase (MAOIs) and selective serotonin (5-hydroxytryptamine, 5-HT) reuptake (SSRIs) induces seroto
181 ed mice had reduced contents of serotonin (5-hydroxytryptamine, 5-HT), a neurotransmitter involved in
182 act contains much of the body's serotonin (5-hydroxytryptamine, 5-HT), but mechanisms controlling the
183 In vitro data suggest that serotonin (5-hydroxytryptamine, 5-HT), via the 5-HT(2A) receptor (5-H
186 O A), the key enzyme catalyzing serotonin (5-hydroxytryptamine; 5-HT) and norepinephrine (NE) degrada
187 The monoamine neurotransmitter serotonin (5-hydroxytryptamine; 5-HT) exerts an inhibitory influence
189 aphe nucleus, which provides serotonergic (5-hydroxytryptamine; 5-HT) innervation to the nucleus accu
193 ry is that a breakdown in brain serotonin (5-hydroxytryptamine; 5-HT) signalling is critically involv
197 e source of nearly all systemic serotonin (5-hydroxytryptamine; 5-HT), which is an important neurotra
198 e source of nearly all systemic serotonin (5-hydroxytryptamine; 5-HT), which is an important neurotra
204 its role as a neurotransmitter, serotonin (5-hydroxytryptamine, 5HT) regulates inflammation and tissu
206 ylamide (LSD) binding to recombinant human 5-hydroxytryptamine 6 (5-HT(6)) receptors expressed in Chi
208 ship (QSAR) models of compounds binding to 5-hydroxytryptamine-6 receptor (5-HT(6)R), a known target
210 -(piperazinylmethyl) indole derivatives as 5-hydroxytryptamine-6 receptor (5-HT6R) antagonists result
211 e previously reported on the unusual human 5-hydroxytryptamine(7) (h5-HT(7)) receptor-inactivating pr
212 ratching was observed following i.d. 5-HT (5-hydroxytryptamine), a protease-activated receptor (PAR)-
213 that a distinct multiprotein complex links 5-hydroxytryptamine-activated intracellular signaling even
214 is responsible for reuptake of serotonin (5-hydroxytryptamine) after its exocytotic release from neu
215 ostasis, such as the melanocortin, leptin, 5-hydroxytryptamine and brain-derived neurotrophic factor
216 ed release of the peristaltic transmitters 5-hydroxytryptamine and calcitonin gene-related peptide; a
217 s, and platelet aggregation and release of 5-hydroxytryptamine at the colonic mucosae were common in
218 ed by acidic citrate, but not alpha-methyl-5-hydroxytryptamine, chloroquine, compound 48/80, or bile
219 mucosal reflexes, which release serotonin (5-hydroxytryptamine) from enterochromaffin cells, and stre
220 single conformations of neutral serotonin (5-hydroxytryptamine) have been studied in the gas phase us
221 tide Y Y2 receptor (NPY(2)R) and serotonin 5-hydroxytryptamine (HT)(2C) receptor (5-HT(2C)R) to cilia
223 a variety of cellular signals elicited by 5-hydroxytryptamine in both peripheral and central tissues
224 cellular dopamine in prefrontal cortex and 5-hydroxytryptamine in hippocampus, compared with their co
225 lular signals elicited by serotonin (5-HT; 5-hydroxytryptamine) in both peripheral and central tissue
226 onoamine neurotransmitter serotonin (5-HT, 5-hydroxytryptamine) in the central nervous system, and dr
228 of the neurotransmitter, serotonin (5-HT; 5-hydroxytryptamine), into cells by the 5-HT transporter (
229 MAOA-L, by causing an ontogenic excess of 5-hydroxytryptamine, labilizes critical neural circuitry f
232 the mutant SNAP-25 could no longer support 5-hydroxytryptamine-mediated inhibition of exocytosis.
233 igated the effect of diminished serotonin (5-hydroxytryptamine) neurotransmission using dietary trypt
234 ignificantly elevated levels of serotonin (5-hydroxytryptamine), norepinephrine, dopamine, and beta-p
236 lectroactive chemical messenger serotonin (5-hydroxytryptamine or 5-HT) for the real-time measurement
239 ll molecules, we identified the serotonin (5-hydroxytryptamine or 5-HT) receptor antagonist metitepin
241 tic (type III) cells to release serotonin (5-hydroxytryptamine, or 5-HT) and norepinephrine (NE).
246 not observed in response to acetylcholine, 5-hydroxytryptamine, or the protease-activated receptor-1
247 ed and produced soluble factors serotonin (5-hydroxytryptamine), platelet factor 4, and platelet-acti
250 al unfolding of a homopentameric LGIC, the 5-hydroxytryptamine receptor (ligand binding, secondary st
251 The objective of this study was to compare 5-hydroxytryptamine receptor 1A (5-HT(1A)) PET with cerebr
253 aper addresses whether the availability of 5-hydroxytryptamine receptor 1B (5-HT(1B)) is seen to decr
254 around 500 kb upstream of the locus HTR1E (5-hydroxytryptamine receptor 1E) locus, related to the ser
255 11, histamine receptor H1, IL-31 receptor, 5-hydroxytryptamine receptor 1F, natriuretic precursor pep
256 can result from the abrupt withdrawal of a 5-hydroxytryptamine receptor 2A antagonist from a treatmen
257 pa-opioid receptors or blockade of 5-HT2A (5-hydroxytryptamine receptor 2A) receptors, suppressed mot
259 on studies linking the c.68C allele of the 5-hydroxytryptamine receptor 2C gene to lower seizure risk
263 thesis in the brain-and serotonin receptor 5-hydroxytryptamine receptor 6 (HTR6) are crucial in media
264 and administration of dexamethasone and a 5-hydroxytryptamine receptor antagonist such as ondansetro
266 f the G alpha(q)-linked serotonin receptor 5-hydroxytryptamine receptor-2b (Htr2b) in maternal islets
269 tic receptors of enteric neurons, Ret, and 5-hydroxytryptamine-receptor subtypes at 33 degrees C and
270 e Y, vasoactive intestinal peptide, or the 5-hydroxytryptamine (serotonin) 3a receptor, were silent.
271 ork directly on the SNARE complex, such as 5-hydroxytryptamine (serotonin) 5-HT(1b) receptors and adr
273 a selective, high-affinity agonist of the 5-hydroxytryptamine (serotonin) receptor 4 that enhances m
274 scent photoproducts of the hydroxyindoles, 5-hydroxytryptamine (serotonin), 5-hydroxytrptophan, and 5
275 Cl(-)-dependent transporters for dopamine, 5-hydroxytryptamine (serotonin), noradrenaline, GABA and g
276 tation (LTF) of sensory neuron synapses by 5-hydroxytryptamine (serotonin; 5-HT) requires the activat
277 internalization is dependent on serotonin 5-hydroxytryptamine subfamily 2 receptors (5-HT(2)Rs), and
278 y of new antiemetic medications, primarily 5-hydroxytryptamine subtype 3 receptor antagonists, as wel
281 t an influence of natural variation in the 5-hydroxytryptamine transporter (5-HTT) gene on multiple a
282 e gene encoding the serotonin transporter [5-hydroxytryptamine transporter (5-HTT)] affect the transc
283 d treatment of C6 glioma cells, which lack 5-hydroxytryptamine transporters, showed marked concentrat
284 ce amine-associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5-HT(1A)) receptors, may repr
285 y spinal delivery of duloxetine acting via 5-hydroxytryptamine type 2A receptors and temporally coinc
286 ansmembrane domain (M3) is conserved among 5-hydroxytryptamine type 3 (5-HT(3)) receptor subunits and
290 is article, we discuss the pharmacology of 5-hydroxytryptamine type 3 receptor antagonists and the im
291 ients may help differentiate responders to 5-hydroxytryptamine type 3 receptor antagonists from non-r
294 -binding cassette subfamily B member 1 and 5-hydroxytryptamine type 3 receptor subunits also contribu
295 y of pentameric ligand-gated ion channels, 5-hydroxytryptamine type 3 receptors (5-HT3Rs) are activat
296 hasone, aprepitant or fosaprepitant, and a 5-hydroxytryptamine type 3-receptor antagonist, in patient
297 (436) and Arg(440)) within the MA helix of 5-hydroxytryptamine type 3A (5-HT3A) receptors act singula